Biological determinants of endocrine resistance in breast cancer (Q37585095)

21 August 2017

1 reference

title

Biological determinants of endocrine resistance in breast cancer (English)

1 reference

21 August 2017

1 reference

Elizabeth A Musgrove

1

1 reference

PubMed ID

19701242

21 August 2017

Robert L Sutherland

series ordinal

2

1 reference

PubMed ID

19701242

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

Nature Reviews Cancer

1 reference

21 August 2017

9

1 reference

21 August 2017

631-643

1 reference

21 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2713

21 August 2017

0 references

cites work

Connections and regulation of the human estrogen receptor

1 reference

Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer

31 March 2020

1 reference

Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones

31 March 2020

1 reference

Aromatase inhibitors for breast cancer prevention

31 March 2020

1 reference

Chemoprevention of breast cancer with selective oestrogen-receptor modulators

31 March 2020

1 reference

The endocrine prevention of breast cancer

31 March 2020

1 reference

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

31 March 2020

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

Aromatase inhibitors for breast cancer: lessons from the laboratory

31 March 2020

1 reference

Endocrine-responsive breast cancer and strategies for combating resistance

31 March 2020

1 reference

CYP2D6 and tamoxifen: DNA matters in breast cancer

31 March 2020

1 reference

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

31 March 2020

1 reference

Selective estrogen receptor modulation: concept and consequences in cancer

31 March 2020

1 reference

Mechanisms of tamoxifen resistance

31 March 2020

1 reference

Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer

31 March 2020

1 reference

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

31 March 2020

1 reference

Selective estrogen-receptor modulators and antihormonal resistance in breast cancer

31 March 2020

1 reference

Pathways to tamoxifen resistance

31 March 2020

1 reference

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

31 March 2020

1 reference

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

31 March 2020

1 reference

Estrogen receptor mutations in human disease

31 March 2020

1 reference

Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer

31 March 2020

1 reference

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

31 March 2020

1 reference

Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?

31 March 2020

1 reference

ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer

31 March 2020

1 reference

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo

31 March 2020

1 reference

Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

31 March 2020

1 reference

Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations

31 March 2020

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

Regulation of estrogen rapid signaling through arginine methylation by PRMT1

31 March 2020

1 reference

Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer

31 March 2020

1 reference

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity

31 March 2020

1 reference

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

31 March 2020

1 reference

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

31 March 2020

1 reference

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

31 March 2020

1 reference

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

31 March 2020

1 reference

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

31 March 2020

1 reference

A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells

31 March 2020

1 reference

FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene

31 March 2020

1 reference

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

31 March 2020

1 reference

Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.

31 March 2020

1 reference

Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3.

31 March 2020

1 reference

Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells

31 March 2020

1 reference

Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity.

31 March 2020

1 reference

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

31 March 2020

1 reference

Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells

31 March 2020

1 reference

c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry

31 March 2020

1 reference

C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells

31 March 2020

1 reference

Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest

31 March 2020

1 reference

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

31 March 2020

1 reference

A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence

31 March 2020

1 reference

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

31 March 2020

1 reference

Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells

31 March 2020

1 reference

Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists

31 March 2020

1 reference

c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells.

31 March 2020

1 reference

Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc

31 March 2020

1 reference

Linking cyclins to transcriptional control.

31 March 2020

1 reference

Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.

31 March 2020

1 reference

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

31 March 2020

1 reference

Cell cycle control in breast cancer cells

31 March 2020

1 reference

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

31 March 2020

1 reference

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

31 March 2020

1 reference

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer

31 March 2020

1 reference

FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus

31 March 2020

1 reference

Mechanisms of tamoxifen-induced apoptosis

31 March 2020

1 reference

Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance

31 March 2020

1 reference

Live or let die: oestrogen regulation of survival signalling in endocrine response

31 March 2020

1 reference

The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells

31 March 2020

1 reference

Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.

31 March 2020

1 reference

Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer

31 March 2020

1 reference

Gene-expression signatures in breast cancer

31 March 2020

1 reference

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer

31 March 2020

1 reference

Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer

31 March 2020

1 reference

Concordance among gene-expression-based predictors for breast cancer

31 March 2020

1 reference

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

31 March 2020

1 reference

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

31 March 2020

1 reference

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

31 March 2020

1 reference

A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.

31 March 2020

1 reference

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response

31 March 2020

1 reference

Outcome signature genes in breast cancer: is there a unique set?

31 March 2020

1 reference

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers

31 March 2020

1 reference

A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival

31 March 2020

1 reference

Progesterone receptors as a prognostic factor in Stage II breast cancer

31 March 2020

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

31 March 2020

1 reference

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

31 March 2020

1 reference

Repeated observation of breast tumor subtypes in independent gene expression data sets

31 March 2020

1 reference

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

31 March 2020

1 reference

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

31 March 2020

1 reference

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

31 March 2020

1 reference

Molecular concepts analysis links tumors, pathways, mechanisms, and drugs

31 March 2020

1 reference

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

31 March 2020

1 reference

Linking oncogenic pathways with therapeutic opportunities

31 March 2020

1 reference

Functional identification of genes causing estrogen independence of human breast cancer cells

31 March 2020

1 reference

Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells

31 March 2020

1 reference

BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells

31 March 2020

1 reference

Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells

31 March 2020

1 reference

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

31 March 2020

1 reference

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer

31 March 2020

1 reference

The prognostic value of BCAR1 in patients with primary breast cancer.

31 March 2020

1 reference

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

31 March 2020

1 reference

Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization

31 March 2020

1 reference

A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells

31 March 2020

1 reference

Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines

31 March 2020

1 reference

Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins

31 March 2020

1 reference

Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells.

31 March 2020

1 reference

NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen

31 March 2020

1 reference

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

31 March 2020

1 reference

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

31 March 2020

1 reference

Modelling Myc inhibition as a cancer therapy

31 March 2020

1 reference

Cyclin-dependent kinase pathways as targets for cancer treatment

31 March 2020

1 reference

Controlling nuclear receptors: the circular logic of cofactor cycles

31 March 2020

1 reference

Estrogen receptor null mice: what have we learned and where will they lead us?

31 March 2020

1 reference

Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

31 March 2020

1 reference

Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen

31 March 2020

1 reference

The NFkappaB pathway and endocrine-resistant breast cancer

31 March 2020

1 reference

Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence

31 March 2020

1 reference

Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome

31 March 2020

1 reference

The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome.

31 March 2020

1 reference

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

31 March 2020

1 reference

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis

31 March 2020

1 reference

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

31 March 2020

1 reference

Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen

31 March 2020

1 reference

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

31 March 2020

1 reference

Activation of PI3K/Akt signaling and hormone resistance in breast cancer

31 March 2020

1 reference

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

31 March 2020

1 reference

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome

31 March 2020

1 reference

Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.

31 March 2020

1 reference

C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance

31 March 2020

1 reference

High p27Kip1 Expression Predicts Superior Relapse-Free and Overall Survival for Premenopausal Women With Early-Stage Breast Cancer Receiving Adjuvant Treatment With Tamoxifen Plus Goserelin

31 March 2020

1 reference

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

31 March 2020

1 reference

Bad expression predicts outcome in patients treated with tamoxifen.

31 March 2020

1 reference

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

31 March 2020

1 reference

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling

31 March 2020

1 reference

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

31 March 2020

1 reference

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer

31 March 2020

1 reference

Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor

31 March 2020

1 reference

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance

31 March 2020

1 reference

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

31 March 2020

1 reference

A candidate molecular signature associated with tamoxifen failure in primary breast cancer

31 March 2020

1 reference

Basic guide to the mechanisms of antiestrogen action

31 March 2020

1 reference

12 December 2020

Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays.

1 reference

12 December 2020

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

1 reference

12 December 2020

Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells

1 reference

12 December 2020

p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells

1 reference

12 December 2020

Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin

1 reference

12 December 2020

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.

1 reference

12 December 2020

Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?

1 reference

12 December 2020

The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells

1 reference

12 December 2020

An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status.

1 reference

12 December 2020

Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.

1 reference

12 December 2020

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance

1 reference

12 December 2020

AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter

1 reference

12 December 2020

Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site

1 reference

12 December 2020

Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer

1 reference

12 December 2020

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

1 reference

12 December 2020

The estrogen receptor: a model for molecular medicine.

1 reference

12 December 2020

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

1 reference

12 December 2020

Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2713

1 reference

21 August 2017

1 reference

PubMed ID

19701242